Strategic collaborations are an important element of our business strategy. Maxygen seeks out-licensing and other agreements with pharmaceutical and biotechnology companies that have commercial development expertise. In exchange for licenses for our protein therapeutics or other specific applications of our proprietary products, Maxygen typically seeks up-front fees, collaborative research funding, milestone payments and royalties on product sales.
Partner Inquiries
If you are interested in exploring a partnership with Maxygen, contact partners@maxygen.com.
 |
|
In December 2007, Maxygen licensed its proprietary dengue virus antigen technology to sanofi pasteur, the vaccines division of the sanofi-aventis Group. Under the terms of the agreement, Maxygen transferred to sanofi pasteur a portfolio of preclinical dengue antigens for development and worldwide commercialization of a second generation vaccine. In addition to royalties, total event payments to Maxygen, including an upfront fee, could total $24.5 million. |
| |
|
|
|
|
|
|
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
Return to About Maxygen
|
